What Does Myovant Sciences Do?

Total employees128
HeadquartersBrisbane
Founded2016

Myovant Sciences was a clinical-stage biopharmaceutical company dedicated to redefining care for women and for men through science, medicines, and advocacy. It focused on developing and commercializing innovative therapies for women's health issues (like uterine fibroids and endometriosis) and prostate cancer. Key products included ORGOVYX® (relugolix) for advanced prostate cancer and MYFEMBREE® (relugolix, estradiol, and norethindrone acetate) for heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. In March 2023, Myovant Sciences was acquired by Sumitovant Biopharma Ltd., a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. Myovant now operates as part of Sumitovant, continuing its mission within the larger Sumitomo Pharma group.

Where Is Myovant Sciences's Headquarters?

HQ Function

The Brisbane office served as the main hub for U.S. operations, including clinical development, commercial strategy, and corporate functions for Myovant Sciences before its acquisition.

Notable Features:

Located within a prominent biotechnology hub in the San Francisco Bay Area, offering access to talent and industry collaboration.

Work Culture:

Historically, Myovant fostered a patient-focused, science-driven, and collaborative work environment aimed at addressing unmet medical needs. This culture is now part of the broader Sumitovant ethos.

HQ Significance:

This location was central to Myovant's U.S. drug development, regulatory approvals, and commercial launch activities for its key products.

Values Reflected in HQ: Innovation, dedication to patient care, and scientific excellence were core values guiding operations at this site.

Location:

Before its acquisition by Sumitovant Biopharma, Myovant Sciences operated with a global outlook, primarily from its U.S. headquarters in Brisbane, California, and its international headquarters in Basel, Switzerland. Its functions included conducting global clinical trials across North America, Europe, and other regions, pursuing regulatory approvals in multiple countries, and building commercial capabilities for its products. These global operations and strategies are now part of Sumitovant Biopharma and its parent company, Sumitomo Pharma.

Street Address:

320 Corey Way, Suite 200

City:

Brisbane

State/Province:

CA

Country:

USA

Where Else Does Myovant Sciences Operate Around the World?

Basel, Switzerland

Address: Viaduktstrasse 8, 4051 Basel, Switzerland

This office was crucial for managing Myovant's ex-U.S. clinical trials, engaging with European regulatory bodies, and planning for potential international market access.

Buying Intent Signals for Myovant Sciences

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Myovant Sciences? Meet the Executive Team

As of April 2025, Myovant Sciences' leadership includes:

David Marek - Former Chief Executive Officer
Frank Karbe - Former President and Chief Financial Officer
Juan Camilo Arjona Ferreira, M.D. - Former Chief Medical Officer
Matthew Lang - Former Chief Administrative and Legal Officer
Uneek Mehra - Former Chief Financial and Business Officer (succeeded Frank Karbe)

Who's Investing in Myovant Sciences?

Myovant Sciences has been backed by several prominent investors over the years, including:

Roivant Sciences Ltd. (Founder and initial majority shareholder)
Sumitomo Dainippon Pharma Co., Ltd. (now Sumitomo Pharma Co., Ltd.) (Significant shareholder prior to full acquisition via Sumitovant)
Pfizer Inc. (Collaboration partner and investor)
Various institutional investors and public shareholders (as a publicly traded company)

What Leadership Changes Has Myovant Sciences Seen Recently?

Hire0
Exits4

The most significant executive changes at Myovant Sciences in the past 12-24 months were linked to its acquisition by Sumitovant Biopharma, completed in March 2023. This led to the transition of the Myovant leadership team as the company was integrated into Sumitovant.

Departures

David Marek, Departed as CEO upon Myovant's acquisition by Sumitovant Biopharma.
Uneek Mehra, Departed as CFBO upon Myovant's acquisition by Sumitovant Biopharma.

New Appointments:

N/A (Leadership integrated into Sumitovant), Following the acquisition, Myovant's leadership structure was absorbed and redefined within Sumitovant Biopharma. New appointments would be within Sumitovant.

What Technology (Tech Stack) Is Used byMyovant Sciences?

Discover the tools Myovant Sciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Myovant Sciences Email Formats and Examples

Prior to its acquisition, Myovant Sciences likely utilized standard corporate email formats. For instance, common patterns include first name initial followed by last name, or first name separated from last name by a period, at the 'myovant.com' domain. Post-acquisition, communications would originate from Sumitovant or Sumitomo Pharma domains.

[first].[last]@myovant.com or [first_initial][last]@myovant.com

Format

jane.doe@myovant.com

Example

5%

Success rate

What's the Latest News About Myovant Sciences?

Sumitomo Pharma Press ReleaseMarch 7, 2023

Myovant Sciences News: Sumitomo Pharma Subsidiary Sumitovant Biopharma Completes Acquisition of Myovant Sciences

Sumitovant Biopharma Ltd., a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd., announced the successful completion of its acquisition of Myovant Sciences Ltd. As a result, Myovant became a wholly-owned subsidiary of Sumitovant and its shares ceased trading on the New York Stock Exchange....more

Myovant Sciences Press Release (via PR Newswire)January 30, 2023

Myovant Sciences News: Myovant Sciences Announces Definitive Agreement to be Acquired by Sumitovant Biopharma for $27.00 Per Share in Cash

Myovant Sciences announced it had entered into a definitive agreement with Sumitovant Biopharma Ltd. under which Sumitovant would acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This valued Myovant at approximately $1.7 billion....more

Myovant Sciences Website (Archived News)August 5, 2022

Myovant Sciences News: Myovant Sciences and Pfizer Announce U.S. FDA Approval of MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis

Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis in pre-menopausal women for up to 24 months....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Myovant Sciences, are just a search away.